Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.
about
Cancer treatment-related cardiac toxicity: prevention, assessment and management.Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysisSignificantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials
P2860
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neoadjuvant Sequential Docetax ...... h Trastuzumab. The DECT Trial.
@en
Neoadjuvant Sequential Docetax ...... h Trastuzumab. The DECT Trial.
@nl
type
label
Neoadjuvant Sequential Docetax ...... h Trastuzumab. The DECT Trial.
@en
Neoadjuvant Sequential Docetax ...... h Trastuzumab. The DECT Trial.
@nl
prefLabel
Neoadjuvant Sequential Docetax ...... h Trastuzumab. The DECT Trial.
@en
Neoadjuvant Sequential Docetax ...... h Trastuzumab. The DECT Trial.
@nl
P2093
P2860
P50
P356
P1476
Neoadjuvant Sequential Docetax ...... h Trastuzumab. The DECT Trial.
@en
P2093
Anna Di Benedetto
Antonella Amodio
Clara Natoli
Claudio Botti
Domenico Sergi
Federica Tomao
Giuseppe Sanguineti
Laura Pizzuti
Letizia Perracchio
Luigi Di Lauro
P2860
P304
P356
10.1002/JCP.25432
P50
P577
2016-05-17T00:00:00Z